We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington's disease.
- Authors
Su Yang; Renbao Chang; Huiming Yang; Ting Zhao; Yan Hong; Ha Eun Kong; Xiaobo Sun; Zhaohui Qin; Peng Jin; Shihua Li; Xiao-Jiang Li; Yang, Su; Chang, Renbao; Yang, Huiming; Zhao, Ting; Hong, Yan; Kong, Ha Eun; Sun, Xiaobo; Qin, Zhaohui; Jin, Peng
- Abstract
Huntington's disease is a neurodegenerative disorder caused by a polyglutamine repeat in the Huntingtin gene (HTT). Although suppressing the expression of mutant HTT (mHTT) has been explored as a therapeutic strategy to treat Huntington's disease, considerable efforts have gone into developing allele-specific suppression of mHTT expression, given that loss of Htt in mice can lead to embryonic lethality. It remains unknown whether depletion of HTT in the adult brain, regardless of its allele, could be a safe therapy. Here, we report that permanent suppression of endogenous mHTT expression in the striatum of mHTT-expressing mice (HD140Q-knockin mice) using CRISPR/Cas9-mediated inactivation effectively depleted HTT aggregates and attenuated early neuropathology. The reduction of mHTT expression in striatal neuronal cells in adult HD140Q-knockin mice did not affect viability, but alleviated motor deficits. Our studies suggest that non-allele-specific CRISPR/Cas9-mediated gene editing could be used to efficiently and permanently eliminate polyglutamine expansion-mediated neuronal toxicity in the adult brain.
- Subjects
HUNTINGTON disease; NEURODEGENERATION; GENETIC disorders; GENETIC mutation; GLUTAMINE; HUNTINGTON'S chorea treatment; ALLELES; ANIMAL experimentation; BIOLOGICAL models; EPITHELIAL cells; GENE expression; GENES; MICE; PEPTIDES; RESEARCH funding
- Publication
Journal of Clinical Investigation, 2017, Vol 127, Issue 7, p2719
- ISSN
0021-9738
- Publication type
journal article
- DOI
10.1172/JCI92087